NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog ...

Floor signage for the offices of DeepSeek (C) is seen in Beijing on January 28, 2025. Fears of upheaval in the AI gold rush rocked Wall Street, following the emergence of a popular ChatGPT-like model ...

(GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Onto Innovation Inc.

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Miami International Holdings, Inc. (MIH), a technology-driven leader in building and operating regulated financial markets ...

Private jets belonging to Zuckerberg, Bezos, Gates and Brin are among those landing at Palm Beach International Airport since ...

For exclusive news and updates, subscribe to our Survivor Newsletter: It’s been nearly 10 years since Michele Fitzgerald was crowned the winner of Survivor Season 32, but she’s still haunted ...

Jamie Dimon, one of the most influential bankers on Wall Street, spelt it out: “It’s time to take a deep breath, do the right thing and continue to have the best financial system in the world.” ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $76.00. The company’s shares ...

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The firm, which says PTC Therapeutics is a top pick in ...